229 related articles for article (PubMed ID: 24222120)
1. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
[TBL] [Abstract][Full Text] [Related]
2. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
3. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
[TBL] [Abstract][Full Text] [Related]
4. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
9. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
Lee JU; Huang S; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Kim SY; Joung KH; Kim JM; Shong M; Jo YS
Eur J Endocrinol; 2012 Jul; 167(1):93-101. PubMed ID: 22535643
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
[TBL] [Abstract][Full Text] [Related]
12. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
13. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
Occhi G; Barollo S; Regazzo D; Bertazza L; Galuppini F; Guzzardo V; Jaffrain-Rea ML; Vianello F; Ciato D; Ceccato F; Watutantrige-Fernando S; Bisognin A; Bortoluzzi S; Pennelli G; Boscaro M; Scaroni C; Mian C
Oncotarget; 2015 Oct; 6(31):32104-14. PubMed ID: 26392334
[TBL] [Abstract][Full Text] [Related]
14. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
15. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
[TBL] [Abstract][Full Text] [Related]
16. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
18. TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
Kim YH; Choi YW; Han JH; Lee J; Soh EY; Park SH; Kim JH; Park TJ
Neoplasia; 2014 Dec; 16(12):1107-20. PubMed ID: 25499223
[TBL] [Abstract][Full Text] [Related]
19. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
20. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]